284461-73-0 Sorafenib AKSci J10391
 
 
Loading Please Wait...
  J10391    AKSci Reference Standard
Sorafenib
, 99% (HPLC), powder
 
BAY 43-9006
Nexavar
Sorafenibum




IDENTITY
CAS Number:284461-73-0
MDL Number:MFCD06411450
MF:C21H16ClF3N4O3
MW:464.82
SPECIFICATIONS & PROPERTIES
Purity:99% (HPLC), powder
Spectra:NMR, LCMS, HPLC
Physical Form:White to off-white powder
Melting Point:202-211°C
Density:1.5
Long-Term Storage:Store long-term at -20°C

BIOLOGICAL INFO
Solubility:DMSO: 127mg/mL; H2O: <1mg/mL; EtOH: <1mg/mL
Application(s):Antineoplastic Agent; Protein Kinase Inhibitor
Form:Free Base

REVIEW

 Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro. Sorafenib was shown to inhibit multiple intracellular (CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, RET, VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-β). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis, and apoptosis. Sorafenib inhibited tumor growth and angiogenesis of human hepatocellular carcinoma and renal cell carcinoma, and several other human tumor xenografts in immunocompromised mice.

REFERENCES
[1]Keating GM, Santoro A (2009). Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 69 (2): 223-40. doi:10.2165/00003495-200969020-00006. PMID 19228077.
[2] Smalley KS, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R, Van Belle P, Elder DE, Wang Y, Nathanson KL, Herlyn M (January 2009). CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 28 (1): 85-94. doi:10.1038/onc.2008.362. PMC 2898184. PMID 18794803.
[3] Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M (October 2008). Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7 (10): 3129-40. doi:10.1158/1535-7163.MCT-08-0013. PMID 18852116.
[4] Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (January 2007). Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356 (2): 125-34. doi:10.1056/NEJMoa060655. PMID 17215530.

GHS

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


Current as of August 19, 2019

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.


Download SDS

For research use only. Not for diagnostic or therapeutic use.
Not for human use.


CATEGORIES

 APIs and Bioactives > Protein Kinase Inhibitors


PubChem